Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse, in comparison with conventional therapy, is less known due to the lack...

Descripción completa

Detalles Bibliográficos
Autores principales: Tun, Aung M., Wang, Yucai, Matin, Aasiya, Inwards, David J., Habermann, Thomas M., Micallef, Ivana, Johnston, Patrick B., Porrata, Luis, Paludo, Jonas, Bisneto, Jose Villasboas, Rosenthal, Allison, Tun, Han W., Cerhan, James R., Witzig, Thomas E., Nowakowski, Grzegorz S., Ansell, Stephen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079336/
https://www.ncbi.nlm.nih.gov/pubmed/37034004
http://dx.doi.org/10.1097/HS9.0000000000000869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079336/
https://www.ncbi.nlm.nih.gov/pubmed/37034004
http://dx.doi.org/10.1097/HS9.0000000000000869

Ejemplares similares